Low Leverage / Strong Balance SheetNear-zero debt materially reduces financial risk and interest burden, giving Intervacc optionality to support R&D, scale manufacturing, or pursue partnerships without immediate debt service pressure. A low-leverage profile improves solvency resilience during extended development cycles common in biotech.

Focused Livestock Vaccine Business ModelA clear, focused business model targeting livestock vaccines aligns with structural demand for animal health solutions tied to food production. Specialization supports repeatable sales cycles via veterinarians and integrated producers, enabling commercially durable revenue streams if market penetration expands.

Historical Top-line GrowthA reported ~70% revenue growth metric demonstrates prior commercial traction and successful product adoption in target markets. Sustained top-line expansion builds scale, which can improve operating leverage and bargaining power with distributors and suppliers if management can stabilize margins and control COGS.

Bears Say

Persistent Negative Cash Flow / Cash BurnConsistent operating and free cash outflows imply the business cannot self-fund development and commercialization. Ongoing cash burn creates dependence on external financing, increasing dilution risk and limiting freedom to invest in manufacturing scale or larger commercialization initiatives without securing new capital.

Structural Margin DeteriorationA large gross loss while revenue rose points to fundamental problems in unit economics—higher COGS, pricing pressure, or operational inefficiencies. Such margin deterioration undermines scalability: revenue growth that worsens gross profit prevents progress toward sustainable profitability.

Eroding Equity Base From Accumulated LossesDeclining equity reduces the company’s loss-absorption capacity and constrains balance-sheet flexibility over time. Even with low debt, an eroding equity base increases risk of dilutive capital raises or constrained strategic options if losses persist, weakening long-term financial stability.

2E9 FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is €30.81M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is May 13, 2026 which is in 52 days.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Feb 17, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.004.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is >-0.01.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went up 43.75%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in DE:2E9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.